MAML3 and prostate cancer: Concerning non-coding variants, four variants belonging to different genes (rs544153916 in PODN, rs116197074 in SCP2, and rs116526711 in MAML3) were noted only in samples from the LRLS group, and one of these variants rs115378978 in the FTO gene was previously associated with prostate cancer according to Disorders and SNPnexus databases (Table 3).